Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CD49d antagonists(Integrin alpha-4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Xerophthalmia | Phase 2 | - | - | |
Dry Eye Syndromes | Preclinical | US | 26 Jun 2018 |
Phase 2 | 102 | (AXR-159 Ophthalmic Solution 50 mg/mL) | dhjdyrzidx(zaiwuqlwpq) = ysxalhqgnw cajwuxlndr (lqnwdhkkni, uphdqtetqc - hmzxjdcxba) View more | - | 13 Oct 2023 | ||
Vehicle (AXR-159 Ophthalmic Solution Vehicle) | dhjdyrzidx(zaiwuqlwpq) = gxvcouxkxp cajwuxlndr (lqnwdhkkni, aeemyoaqtr - zasheisrwq) View more |